CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

GlobeNewswire Clinical Studies
Original article

ABLi Therapeutics Announces Outcomes from its Parkinson’s-related Biomarker Study Demonstrating Modification of Human Disease with Risvodetinib

Risvodetinibrisvodetinib

Read the original article

Published by GlobeNewswire Clinical Studies on August 4, 2026 12:05 PM

Read Original